PABPN1 suppresses TDP-43 toxicity in ALS disease models

Ching-Chieh Chou1, Olga M Alexeeva2, Shizuka Yamada3

  • 1Department of Cell Biology, Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA 30322, USA.

Insights

Poly(A)-binding protein nuclear 1 (PABPN1) suppresses toxic TDP-43 proteinopathy in neurodegenerative diseases like ALS. Overexpressing PABPN1 clears pathological TDP-43 and restores normal protein function, offering a potential therapeutic strategy.

Area of Science:

  • Neurobiology
  • Molecular Biology
  • Genetics

Background:

  • TAR DNA-binding protein 43 (TDP-43) accumulation and mislocalization are key features of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS).
  • Impaired RNA and protein homeostasis due to TDP-43 dysfunction contribute to disease progression.
  • Targeting TDP-43 pathology is crucial for halting or reversing neurodegenerative conditions.

Purpose of the Study:

  • To identify novel TDP-43 interaction partners that can suppress TDP-43 toxicity.
  • To investigate the role of poly(A)-binding protein nuclear 1 (PABPN1) in mitigating TDP-43 proteinopathies.

Main Methods:

  • Investigated PABPN1 as a TDP-43 interaction partner.
  • Utilized cell culture and Drosophila models of ALS.
  • Assessed the effects of PABPN1 overexpression on TDP-43 toxicity, localization, degradation, and stress granule dynamics.

Main Results:

  • PABPN1 acts as a potent suppressor of TDP-43 toxicity.
  • Overexpression of full-length PABPN1, but not a truncated mutant, protects against TDP-43-mediated toxicity.
  • PABPN1 promotes the degradation of pathological TDP-43, restores its normal nuclear localization, and rescues dysregulated stress granule dynamics.

Conclusions:

  • PABPN1 is a novel therapeutic target for TDP-43 proteinopathies.
  • PABPN1 enhances the turnover of pathological proteins, offering a strategy to reverse cytopathological features in ALS and related diseases.